Lamisil At is a drug marketed by Novartis and is included in two NDAs. It is available from two suppliers. There is one patent protecting this drug.
The generic ingredient in LAMISIL AT is terbinafine hydrochloride. There are twenty-three drug master file entries for this compound. Five suppliers are listed for this compound. There is one tentative approval for this compound. Additional details are available on the terbinafine hydrochloride profile page.
|Applicant||Tradename||Generic Name||Dosage||NDA||Approval Date||Type||RLD||Patent No.||Patent Expiration||Product||Substance||Delist Req.||Exclusivity Expiration|
|GEL;TOPICAL||021958||Jul 24, 2006||OTC||Yes||5,681,849*PED||<disabled>||Y||<disabled>|
|SOLUTION;TOPICAL||021124||Mar 17, 2000||OTC||Yes||5,681,849*PED||<disabled>||Y||<disabled>|
|SPRAY;TOPICAL||021124||Mar 17, 2000||OTC||Yes||5,681,849*PED||<disabled>||Y||<disabled>|
|This preview shows a limited data set|
Subscribe for full access, or try a free trial
Export unavailable in trial.
Subscribe for complete access.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.